Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
seladelpar + ursodeoxycholic acid
- Development stage
- Phase 3
- Lead developer
- Johnson & Johnson
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Seladelpar + ursodeoxycholic acid is a combination therapeutic regimen used for the treatment of primary biliary cholangitis (PBC) in adults who have had an inadequate response to ursodeoxycholic acid (UDCA) monotherapy. Seladelpar is an orally active, selective peroxisome proliferator-activated receptor delta (PPAR-delta) agonist that regulates genes involved in bile acid synthesis, inflammation, and fibrosis. Ursodeoxycholic acid is a naturally occurring, hydrophilic bile acid that decreases the cholesterol content of bile and reduces the toxic effects of endogenous hydrophobic bile acids on hepatocytes and cholangiocytes. Together, the co-administration of these two agents provides a synergistic therapeutic effect, significantly reducing alkaline phosphatase (ALP) levels and improving symptoms such as pruritus in patients with PBC.
- Other names
- Livdelzi + UDCALivdelzi + ursodeoxycholic acidLivdelzi + ursodiolseladelpar + UDCAseladelpar + ursodiolseladelpar and UDCAseladelpar and ursodeoxycholic acidseladelpar and ursodiol
02
Targets
BAR (Bile acid receptor)GPBAR1PPARD (Peroxisome proliferator–activated receptor delta)
Beyond the preview
Go deeper on seladelpar + ursodeoxycholic acid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on seladelpar + ursodeoxycholic acid.